Matthias von Herrath

Matthias von Herrath, MD, is a distinguished physician-scientist with a strong reputation in immunology and drug development for type 1 diabetes. He has an extensive background in academic medical research and the pharmaceutical industry, particularly in clinical translation of immune-based interventions for autoimmune and metabolic diseases. Currently, Dr. von Herrath is Vice President and Senior Medical Officer at Novo Nordisk, a major global healthcare company, where he contributes his extensive industry knowledge to the development of new therapies, focusing on their safety and efficacy. In addition, he is the Scientific Director of the Diabetes Research Institute (DRI), University of Miami School of Medicine. In this role, he spearheads innovative research aimed at delaying, preventing, and ultimately curing type 1 diabetes, leading a team dedicated to advancing scientific discoveries. Dr. von Herrath's career is highlighted by significant contributions to immunology and drug development, effectively bridging the gap between academia and the pharmaceutical industry. He has been involved with the organ donor network (nPOD) for a long time, focusing on understanding T1D pathology. His work has been recognized with numerous awards, including the American Diabetes Association’s Outstanding Scientific Achievement Award in 2008, the German Diabetes Society’s Langerhans Award in 2014, and a lifetime achievement award from nPOD in 2018. These accolades underscore his impact on the field and dedication to improving the lives of those with type 1 diabetes.